bis((7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)methyl) tetradecanedioate | 1383741-16-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: bis((7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)methyl) tetradecanedioate
• 英文别名: Bis[[7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-2-oxo-3,4-dihydroquinolin-1-yl]methyl] tetradecanedioate
• CAS: 1383741-16-9
• 化学式: C₆₂H₈₀Cl₄N₆O₈
• 分子量: 1179.16
• InChiKey: MQXANIJYJMPUNM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  14.3
• 重原子数：
  80
• 可旋转键数：
  33
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  125
• 氢给体数：
  0
• 氢受体数：
  12

反应信息

• 作为产物：
  描述：

  阿立哌唑 在 三乙胺 作用下， 以 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 48.0h， 生成 bis((7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)methyl) tetradecanedioate
  参考文献：
  名称：

  [EN] MULTI- API LOADING PRODRUGS
  [FR] PROMÉDICAMENTS CHARGÉS DE MULTIPLES PRINCIPES ACTIFS

  摘要：

  本发明通过将多个母药分子附着在载体基团上，并延长母药在患者服用后释放和吸收的时间，从而实现此目的，并提供每剂次比母药本身更长的作用时间。前药偶联物适用于异杂环、内酰胺、酰胺、磺酰胺、氨基甲酸酯、脲、苯甲酰胺、酰基苯胺、环状酰胺和三级胺含有母药，该母药在酰胺氮或氧原子处以不稳定的醛类前药基团取代。前药的载体基团可以是疏水性的，在生理条件下降低母药的极性和溶解度。

  公开号：

  WO2012088441A1

文献信息

• Multi-API loading prodrugs
  申请人：Alkermes Pharma Ireland Limited

  公开号：US10584099B2

  公开（公告）日：2020-03-10

  The present invention accomplishes this by having multiple molecules of parent drugs attached to carrier moieties and by extending the period during which the parent drug is released and absorbed after administration to the patient and providing a longer duration of action per dose than the parent drug itself. Prodrug conjugates are suitable for sustained delivery of heteroaryl, lactam-amide-, imide-, sulfonamide-, carbamate-, urea-, benzamide-, acylaniline-, cyclic amide- and tertiary amine-containing parent drugs that are substituted at the amide nitrogen or oxygen atom with labile aldehyde-linked prodrug moieties. The carrier groups of the prodrugs can be hydrophobic to reduce the polarity and solubility of the parent drug under physiological conditions.

  本发明通过将多个母体药物分子连接到载体分子上，并通过延长母体药物在给患者用药后的释放和吸收时间，以及提供比母体药物本身更长的单位剂量作用时间，来实现上述目的。原药共轭物适用于持续给药杂芳族、内酰胺-酰胺、亚胺、磺胺、氨基甲酸酯、脲、苯甲酰胺、酰苯胺、环酰胺和叔胺母药，这些母药在酰胺氮或氧原子上被易变醛连接的原药分子取代。原药的载体基团可以是疏水性的，以降低母药在生理条件下的极性和溶解度。
• MULTI-API LOADING PRODRUGS
  申请人：Alkermes Pharma Ireland Limited

  公开号：EP2655314B1

  公开（公告）日：2018-02-07
• Multi-API Loading Prodrugs
  申请人：Zeidan Tarek A.

  公开号：US20120202823A1

  公开（公告）日：2012-08-09

  The present invention accomplishes this by having multiple molecules of parent drugs attached to carrier moieties and by extending the period during which the parent drug is released and absorbed after administration to the patient and providing a longer duration of action per dose than the parent drug itself. Prodrug conjugates are suitable for sustained delivery of heteroaryl, lactam- amide-, imide-, sulfonamide-, carbamate-, urea-, benzamide-, acylaniline-, cyclic amide- and tertiary amine-containing parent drugs that are substituted at the amide nitrogen or oxygen atom with labile aldehyde-linked prodrug moieties. The carrier groups of the prodrugs can be hydrophobic to reduce the polarity and solubility of the parent drug under physiological conditions.
• [EN] MULTI- API LOADING PRODRUGS<br/>[FR] PROMÉDICAMENTS CHARGÉS DE MULTIPLES PRINCIPES ACTIFS
  申请人：ALKERMES INC

  公开号：WO2012088441A1

  公开（公告）日：2012-06-28

  The present invention accomplishes this by having multiple molecules of parent drugs attached to carrier moieties and by extending the period during which the parent drug is released and absorbed after administration to the patient and providing a longer duration of action per dose than the parent drug itself. Prodrug conjugates are suitable for sustained delivery of heteroaryl, lactam- amide-, imide-, sulfonamide-, carbamate-, urea-, benzamide-, acylaniline-, cyclic amide- and tertiary amine-containing parent drugs that are substituted at the amide nitrogen or oxygen atom with labile aldehyde-linked prodrug moieties. The carrier groups of the prodrugs can be hydrophobic to reduce the polarity and solubility of the parent drug under physiological conditions.

  本发明通过将多个母药分子附着在载体基团上，并延长母药在患者服用后释放和吸收的时间，从而实现此目的，并提供每剂次比母药本身更长的作用时间。前药偶联物适用于异杂环、内酰胺、酰胺、磺酰胺、氨基甲酸酯、脲、苯甲酰胺、酰基苯胺、环状酰胺和三级胺含有母药，该母药在酰胺氮或氧原子处以不稳定的醛类前药基团取代。前药的载体基团可以是疏水性的，在生理条件下降低母药的极性和溶解度。